MNKD Afrezza: Enterprise Value to EBITDA Ratio
MannKind Corporation (MNKD) current EV/EBITDA level confirms the transformation of MNKD into a profitable business with high market confidence. Growth is based on the creation of an inhalation insulin that eliminates injections and strategic partnerships to implement the Technosphere system. The value 92.60 shows the current magnitude of this metric, which strips debt risks from the asset valuation, confirming the fundamental stability of the shares.
Comprehensive metric breakdowns and analytics for mannkindcorp.com (MNKD)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
MNKD - Company Profit|Expected Profit MannKind Corporation|MNKD - P/E Multiple|Forward P/E Multiple MannKind Corporation|MNKD - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Afrezza|MNKD - Operating profit before amortization|Net earnings per share (EPS TTM) MannKind|MNKD - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months mannkindcorp.com|MNKD - Earnings per share increase in current year|Earnings growth forecast for next year MannKind Corporation
- company sales and revenue statistics:
Analysis of all company metrics:MannKind Corp. MNKD
Stable cash flow from inhaled insulin sales and royalties allows for the determination of the real value of MannKind Corporation (MNKD) using the EV/EBITDA multiple, accounting for its debt load. This indicator compares the total enterprise value (market capitalization plus net debt) with operating profit, revealing cash generation efficiency before the impact of taxes and borrowing costs, which is critical for assessing the sustainability of capital-intensive assets.
Competitors of MannKind Corporation
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|AMPH - Enterprise Value to EBITDA Ratio|Pacira - EV/EBITDA Multiple|SPRY - EV/EBITDA Multiple|Theravance Biopharma (TBPH) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation AQST|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization scPharmaceuticals, Inc.|Enterprise Value to Operating Income Before Depreciation TECX (Tectonic)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tonix Pharmaceuticals Inc. (TNXP)|EV/EBITDA Multiple sxtchina.com (SXTC)|EV/EBITDA Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio bioharvest.com (BHST)|EXOZ - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ORMP (Oramed Pharmaceuticals) - Enterprise Value to Operating Income Before Depreciation|ENTX: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation HYFT|Enterprise Value to EBITDA Ratio ABVC|CPIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple QNTM|Enterprise Value to EBITDA Ratio FibroGen Inc FGEN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|Rani Therapeutics Holdings (RANI) - Company Value to EBITDA|SNYR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation RLYB (Rallybio Corporation)|lexariabioscience.com (LEXX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PULM (Pulmatrix Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pheton Holdings Limited|Company Value to EBITDA Aptorum APM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|IBO (impactbiomedinc.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|EV/EBITDA Multiple cbdMD Inc. YCBD|PRFX: Enterprise Value to EBITDA Ratio|Altamira Therapeutics - Enterprise Value to Operating Income Before Depreciation Ratio|LIPO: EV/EBITDA Multiple|OPTN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Company Value to EBITDA Procaps Group PROC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|Qilian International Corp - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|TFFP - Enterprise Value to EBITDA Ratio
